Therapy areas

Skin-related symptoms

Acne affects many women, including young women1-3

Acne is prevalent among women, especially adolescents.1-3 It affects between 50% and 95% of adolescents,1 with many (up to 40%) still affected into their mid-twenties.2

 

Icon of a woman with Acne

 

Acne is a known cause of psychological distress, including anxiety and depression4-8

Acne has a significant impact on women’s lives, including anxiety, depression and a reduction in social functioning.4,5

 

In addition, acne makes women feel less confident, more self-conscious around other people, frustrated and embarrassed,*6 while also impacting their self-esteem.7

 

The scars left by acne have also been shown to induce further negative psychological effects.8

 

*A cross-sectional, electronic, web-based observational survey conducted in the US (N=107), acne and breakouts were associated with negative self-perceptions. >75% of participants “agreed” or “strongly agreed” that acne made them feel less confident, more self-conscious around other people, frustrated, and embarrassed.6

Yasmin® and YAZ® have beneficial effects on mild-to-moderate acne in women seeking contraception

Yasmin® and YAZ® have antiandrogenic activity without androgenic potential1

 

  • Drospirenone, the progestin in Yasmin® and Yaz®, has a pharmacological profile similar to that of endogenous progesterone1-3
  • It combines potent progestogenic activities with antimineralocorticoid and antiandrogenic activities2
  • Drospirenone competitively inhibits the binding of androgens to androgen receptors1
  • A decrease of ovarian androgen production reduces the severity of acne and seborrhea3

 

By measurably reducing inflammatory and non-inflammatory lesion counts, Yasmin® and YAZ® help reduce the negative impact of acne on female mental health and self-esteem4-6

Please click here for more information about YAZ®

 

Please click here for more information about Yasmin®

 

  • Muhn P et al. Ann N Y Acad Sci 1995;12;761:311–335. Return to content
  • Fuhrmann U, Krattenmacher R, Slater EP et al. Contraception 1996;54(4):243–251. Return to content
  • Krattenmacher R. Contraception 2000;62(1):29–38. Return to content
  • van Vloten WA, van Haselen C, van Zuuren E et al. Cutis 2002;69:2–15. Return to content
  • Boschitsch E, Skarabis H, Wuttke W et al. Eur J Contracept Reprod Health Care 2000;5:34–40. Return to content
  • Koltun W, Maloney JM, Marr J et al. Eur J Obstet Gynecol Reprod Biol 2011;155(2):171–175. Return to content

Diane-35 offers effective treatment for women with moderate-to-severe acne caused by androgen excess1-4

In clinical trials, Diane-35® was associated with healing of or clinically significant improvements in acne lesions after 3–6 months of treatment,1-3 with a greater treatment effect with longer duration of treatment.1-4

 

  • In a multicenter clinical trial, Diane-35® was associated with a statistically significant reduction in acne lesions (67%) compared with EE/LNG (27%; P<0.05) after four cycles of treatment.2 After 6 cycles, Diane-35® was associated with a 72% reduction in acne lesions vs 35% with EE/LNG (P<0.0001)2

 

The therapeutic effect of Diane-35® has not only been observed in facial acne, but to a similar extent in acne lesions on the chest and back.4 Complete clearance of acne on the face, chest and back has been observed in approximately 90% of women after 9 treatment cycles.4

 

Please click here for more information about Diane-35®

 

 

EE/LNG – ethinylestradiol/levonorgestrel